A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
A Phase 1/2 Open-label Trial of KVA12123 [TBS-2025] Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors. The study included dose escalation and planned dose expansion phases. Only the dose escalation phases were conducted. The planned dose expansion phase were not initiated following a business decision to discontinue development in solid tumors. This decision was unrelated to any identified safety concern.
The study sought to assess the safety of KVA12123 [TBS-2025] given alone or with pembrolizumab and to identify appropriate doses for future clinical trials. Participants in the doses for future clinical trials. Participants in the dose escalation phases visited study sites for treatment and safety assessments. These assessments included blood samples, imaging scans, physical examinations, and heart function tests.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This was a first-in-human (FIH), Phase 1/2, open-label, multicenter, dose escalation, and dose expansion study designed to evaluate the safety, tolerability, PK, immunogenicity, and tumor response of the investigational drug KVA12123, subsequently designated TBS-2025, alone and in combination with pembrolizumab in adults with relapsed or refractory advanced solid tumors. The study was planned to conduct in 4 planned parts: Parts A and B focus on dose escalation (single-agent and in combination), and Parts C and D focus on dose expansion (single-agent and in combination).
Parts A (single-agent KVA12123) and B (KVA12123 + pembrolizumab) allowed up to 10 dose escalation cohorts: 6 in Part A and 4 in Part B, with 1 to 6 participants per cohorts. These parts were intended to characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary tumor response, and to inform the selection of recommended phase 2 doses.
Parts C (single-agent KVA12123) and D (KVA12123 + pembrolizumab) were planned but not initiated following a business decision to discontinue development in solid tumors. This decision was unrelated to any identified safety concern.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Santa Monica, California, United States, 90404
- UCLA Health (Santa Monica Cancer Care)
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Sarah Cannon Research Institute at HealthONE
-
-
Florida
-
Sarasota, Florida, United States, 34232
- Sarah Cannon Research Institute at Florida Cancer Specialists
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute at Tennessee Oncology
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutchinson Cancer Research Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
-
Willing and able to provide informed consent.
-
Be at least 18 years of age at the time of consent.
-
Has histologically or cytologically confirmed, locally advanced or metastatic solid tumor that has progressed or was non-responsive to standard of care therapy and for which no available curative therapy exists.
-
Has expected survival ≥16 weeks.
-
Presence of measurable disease by iRECIST.
-
Has an ECOG performance status score of 0 or 1.
-
Has adequate organ function within 10 days prior to the start of study treatment.
-
Has normal thyroid function or hypothyroid with stable supplementation.
-
Has consented to the collection of archival tissue prior to study treatment initiation.
-
Participants with prior exposure to systemic anticancer therapy including investigational agents following a 4-week washout period are eligible. Participants with prior small molecule targeted therapy or other short half-life drugs are eligible following a 2-week washout period.
-
Participants having prior curative radiation therapy completed 2 weeks prior to study drug administration or prior palliative radiation therapy to non-CNS disease completed at least 1 week prior to study drug administration are eligible.
-
HIV-infected participants must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease.
-
Participants with a history of HBV infection having durable HBsAg loss and undetectable serum HBV DNA no longer requiring treatment are eligible.
-
Participants with history of HCV infection are eligible if HCV viral load is undetectable at screening and participants have completed curative antiviral therapy.
-
Post-menopausal women and surgically sterile men and women are permitted.
-
Patients of childbearing potential are permitted to participate under the following conditions:
- Must have negative urine pregnancy test result within 72 hrs prior to the first dose of any study drug
- Must agree not to become pregnant during the study and for 120 days after the final dose of any study drug
- Must agree not to breastfeed or donate ova, starting at time of informed consent and continuing through 120 days after the final dose of any study drug
- If sexually active in a way that could lead to pregnancy, must consistently use 2 acceptable methods of birth control (contraception), at least 1 of which must be highly effective starting at time of informed consent and continuing throughout the study and for 120 days after the final dose of any study drug.
-
Patients who can father children are permitted to participate under the following conditions:
- Must agree not to donate sperm starting at the time of informed consent and continuing throughout the study period and for 120 days after the final dose of any study drug
- If sexually active with a person of childbearing potential in a way that could lead to pregnancy, must consistently use 2 acceptable methods of birth control (contraception), at least 1 of which must be highly effective starting at the time of informed consent and continuing throughout the study and for 120 days after the final dose of any study drug
- If sexually active with a person who is pregnant or breastfeeding, must consistently use a condom starting at time of informed consent and continuing throughout the study and for 120 days after the final dose of any study drug.
-
Must be willing and able to comply with the trial procedures and the follow-up schedule.
Exclusion Criteria
- Untreated CNS metastatic disease, leptomeningeal disease, or cord compression.
- Concurrent cancer other than disease under study requiring systemic treatment. Participants with basal cell or squamous cell skin cancer treated with curative intent, carcinoma in-situ of the cervix or breast treated with curative intent, RAI stage 0 Chronic Lymphocytic Leukemia, monoclonal gammopathy of undetermined significance, superficial bladder cancer or very low and low risk prostate cancer (localized Gleason score ≤ 6) under active surveillance are eligible.
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg QD of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug.
- History of (non-infectious) pneumonitis/interstitial lung disease (ILD) that required steroids or current pneumonitis/ILD.
- Prior treatment with VISTA-targeted therapy.
- Prior history of allogeneic, solid organ or stem cell transplant, or adoptive T-cell transplant.
- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, LAG-3, OX 40, CD137), and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE).
- Active known or suspected autoimmune disease that has required systemic treatment within the past year. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- Prior systemic anticancer therapy, including investigational agents, within 4 weeks of treatment. Participants with prior small molecule targeted therapy or other short half-life drugs are eligible following a 2-week washout period.
- Has received prior radiation therapy within 2 weeks of start of study treatment or has a history of radiation pneumonitis.
- Has received radiation therapy to the lung that is >30 Gy within 6 months of the first dose of study treatment.
- Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention.
- Any requirement for daily supplemental oxygen.
- Any condition requiring systemic treatment with corticosteroids (>10 mg QD prednisone equivalents) or other immunosuppressive medications within 14 days before the first dose of study drug.
- Serious or poorly controlled cardiovascular disease.
- Chronic hepatitis B or C.
- HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
- Has an active infection requiring systemic therapy.
- Known active or latent tuberculosis.
- If the participant had major surgery, must have recovered adequately from the procedure and/or any complications.
- Toxicities arising from prior cancer therapy that have not resolved to Grade 1 or baseline.
- Red blood cell or platelet infusion within the preceding 2 weeks.
- Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
- Known hypersensitivity to any excipient contained in the drug formulation of KVA12123.
- Any significant history of drug allergy as assessed by the investigator.
- Positive urine pregnancy test within 72 hrs of study drug administration.
- Participants who are breastfeeding, pregnant, or planning to become pregnant from time of informed consent until at least 120 days after final dose of study drug.
- Has a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study.
- Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
- Inability to comply with study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: KVA12123 [TBS-2025] Monotherapy Dose Escalation
Part A will consist of dose escalation with KVA12123 [TBS-2025] administered as a single agent in participants with advanced solid tumors. |
Ascending KVA12123 doses given as monotherapy by intravenous administration every 2 weeks of each 6-week cycle. |
|
Experimental: KVA12123 [TBS-2025] Plus Pembrolizumab Dose Escalation
Part B will consist of dose escalation with KVA12123 administered in combination with a fixed dose of pembrolizumab. |
Ascending KVA12123 doses given by intravenous administration every 2 weeks of each 6-week cycle in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.
Other Names:
|
|
Experimental: KVA12123 [TBS-2025] Monotherapy Dose Expansion
Part C will consist of dose expansion with KVA12123 [TBS-2025] administered as a single agent at the RP2D in participants with advanced solid tumors. Part C was not initiated. |
KVA12123 administered at the RP2D by intravenous administration every 2 weeks of each 6 week cycle. |
|
Experimental: KVA12123 Plus Pembrolizumab Dose Expansion
Part D will consist of dose expansion with KVA12123 [TBS-2025] administered at the RP2D in combination with a fixed dose of pembrolizumab. Part D was not initiated. |
KVA12123 administered at the RP2D by intravenous administration every 2 weeks in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Events
Time Frame: Through study completion, an average of 1 year
|
Type and frequency of adverse events as assessed by CTCAE v5.0. |
Through study completion, an average of 1 year
|
|
AEs related to study drug
Time Frame: Through study completion, an average of 1 year
|
Type and frequency of treatment related adverse events as assessed by CTCAE v4.0. |
Through study completion, an average of 1 year
|
|
Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD)
Time Frame: Through study completion, an average of 1 year
|
Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD) of KVA12123 when administered alone and in combination with pembrolizumab in participants with advanced solid tumors (milligrams or milligrams/kilogram). |
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetic (PK) profile of KVA12123 (Cmax)
Time Frame: Through study completion, an average of 1 year
|
maximum serum concentration (micrograms/milliliter [mL]) |
Through study completion, an average of 1 year
|
|
Pharmacokinetic (PK) profile of KVA12123 (Cmin)
Time Frame: Through study completion, an average of 1 year
|
trough serum concentration (micrograms/mL) |
Through study completion, an average of 1 year
|
|
Pharmacokinetic (PK) profile of KVA12123 (tmax)
Time Frame: Through study completion, an average of 1 year
|
time to maximum serum concentration (hours) |
Through study completion, an average of 1 year
|
|
Pharmacokinetic (PK) profile of KVA12123 (AUC)
Time Frame: Through study completion, an average of 1 year
|
Area under the concentration-time curve (microgram*mL/hour) |
Through study completion, an average of 1 year
|
|
Pharmacokinetic (PK) profile of KVA12123 (t1/2)
Time Frame: Through study completion, an average of 1 year
|
Elimination half life (hours) |
Through study completion, an average of 1 year
|
|
Pharmacokinetic (PK) profile of KVA12123 (Vd)
Time Frame: Through study completion, an average of 1 year
|
Volume of distribution (milliliter or liter) |
Through study completion, an average of 1 year
|
|
Pharmacokinetic (PK) profile of KVA12123 (Cl)
Time Frame: Through study completion, an average of 1 year
|
Clearance (mL/hour) |
Through study completion, an average of 1 year
|
|
Concentration of anti-KVA12123 antibodies in serum
Time Frame: Through study completion, an average of 1 year
|
Change from baseline in anti-KVA12123 antibodies in serum (antibody concentration per mL) |
Through study completion, an average of 1 year
|
|
Number of participants with progressive disease following treatment with KVA12123
Time Frame: Through study completion, an average of 1 year
|
Investigator assessment of radiographic imaging according to iRECIST. |
Through study completion, an average of 1 year
|
|
Number of participants with progressive disease following treatment with KVA12123 in combination with pembrolizumab
Time Frame: Through study completion, an average of 1 year
|
Investigator assessment of radiographic imaging according to iRECIST. |
Through study completion, an average of 1 year
|
|
Number of participants with stable disease following treatment with KVA12123
Time Frame: Through study completion, an average of 1 year
|
Investigator assessment of radiographic imaging according to iRECIST. |
Through study completion, an average of 1 year
|
|
Number of participants with stable disease following treatment with KVA12123 plus pembrolizumab
Time Frame: Through study completion, an average of 1 year
|
Investigator assessment of radiographic imaging according to iRECIST. |
Through study completion, an average of 1 year
|
|
Number of participants with partial response following treatment with KVA12123
Time Frame: Through study completion, an average of 1 year
|
Investigator assessment of radiographic imaging according to iRECIST. |
Through study completion, an average of 1 year
|
|
Number of participants with partial response following treatment with KVA12123 plus pembrolizumab
Time Frame: Through study completion, an average of 1 year
|
Investigator assessment of radiographic imaging according to iRECIST. |
Through study completion, an average of 1 year
|
|
Number of participants with complete response following treatment with KVA12123
Time Frame: Through study completion, an average of 1 year
|
Investigator assessment of radiographic imaging according to iRECIST. |
Through study completion, an average of 1 year
|
|
Number of participants with complete response following treatment with KVA12123 plus pembrolizumab
Time Frame: Through study completion, an average of 1 year
|
Investigator assessment of radiographic imaging according to iRECIST. |
Through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Thierry Guillaudeux, PhD, Kineta Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Endocrine System Diseases
- Genital Neoplasms, Male
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Diseases, Male
- Prostatic Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Intestinal Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Stomach Diseases
- Colorectal Neoplasms
- Intestinal Neoplasms
- Uterine Diseases
- Genital Diseases, Female
- Lung Diseases
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Colonic Diseases
- Esophageal Diseases
- Ovarian Diseases
- Adnexal Diseases
- Genital Neoplasms, Female
- Gonadal Disorders
- Skin Diseases
- Breast Diseases
- Urologic Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Neoplasms, Connective and Soft Tissue
- Nevi and Melanomas
- Skin Neoplasms
- Thyroid Diseases
- Skin and Connective Tissue Diseases
- Neoplasms
- Prostatic Neoplasms
- Stomach Neoplasms
- Carcinoma
- Lung Neoplasms
- Colonic Neoplasms
- Esophageal Neoplasms
- Ovarian Neoplasms
- Breast Neoplasms
- Pancreatic Neoplasms
- Head and Neck Neoplasms
- Melanoma
- Sarcoma
- Kidney Neoplasms
- Thyroid Neoplasms
- Uterine Neoplasms
- pembrolizumab
Other Study ID Numbers
Other Study ID Numbers
- VISTA-101
- KEYNOTE-E67 (Other Identifier: Merck, Sharp & Dohme, LLC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.